Ji Hee Son

1 week ago | digitalcommons.library.tmc.edu | Ji Hee Son |Rodney Cheng-En Hsieh |Heather Lin |Kate Krause

AbstractCD47-SIRPα interaction acts as a "don't eat me" signal and is exploited by cancer to downregulate innate and adaptive immune surveillance. There has been intense interest to develop a mechanism of blockade, and we aimed to analyze the emerging data from early clinical trials. We performed a systematic review and meta-analysis of relevant databases and conference abstracts including clinical trials using CD47 and/or SIRPα inhibitors in cancer treatment.

Sep 11, 2024 | digitalcommons.library.tmc.edu | Ji Hee Son |Heather Lin |Siqing Fu |Amadeo B. Biter

INTRODUCTION: We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to phase I clinical trials. METHODS: Patients with cervical cancer who received at least one dose of a phase I investigational agent at our institution between 2014 and 2022 were included.